Procaterol hydrochloride

DescriptionPartial PROTAC Pomalidomide-PEG6-butyl amine (HCl salt) enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology. This conjugate contains a Cereblon (CRBN)-recruiting

DescriptionPartial PROTAC Pomalidomide-PEG6-butyl amine (HCl salt) enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology. This conjugate contains a Cereblon (CRBN)-recruiting

DescriptionPartial PROTAC Pomalidomide-PEG6-butyl amine (HCl salt) enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology. This conjugate contains a Cereblon (CRBN)-recruiting

DescriptionProtein degrader builiding block Pomalidomide-PEG6-NH2(HCl salt) enables the synthesis of molecules fortargeted protein degradation andPROTAC (proteolysis-targeting chimeras) technology. This conjugate contains a Cereblon

Na+ channel blocker.

Na+ channel blocker.

Na+ channel blocker.

General description Procaterol is used to prevent lung fibroblast migration. It has anti-inflammatory properties.

Procaterol hydrochloride is a selective intermediate-acting β2 adrenoreceptor agonist with an EC50 of 12.9 µM[1]. Procaterol hydrochloride can inhibit inflammation both in vivo and in vitro.

Procaterol hydrochloride is a selective intermediate-acting β2 adrenoreceptor agonist with an EC50 of 12.9 µM[1]. Procaterol hydrochloride can inhibit inflammation both in vivo and in vitro.

Procaterol hydrochloride is a selective intermediate-acting β2 adrenoreceptor agonist with an EC50 of 12.9 µM[1]. Procaterol hydrochloride can inhibit inflammation both in vivo and in vitro.

Procaterol hydrochloride is a selective intermediate-acting β2 adrenoreceptor agonist with an EC50 of 12.9 µM[1]. Procaterol hydrochloride can inhibit inflammation both in vivo and in vitro.